Result of Neoadjuvant Chemotherapy, Surgery and Radiation Therapy in Locally Advanced Breast Cancer.
10.3857/jkstro.2010.28.2.71
- Author:
Sun Hyun BAE
1
;
Won PARK
;
Seung Jae HUH
;
Doo Ho CHOI
;
Heerim NAM
;
Jung Hyun YANG
;
Seok Jin NAM
;
Jeong Eon LEE
;
Young Hyuck IM
;
Jin Seok AHN
;
Yeon Hee PARK
Author Information
1. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. wonro.park@samsung.com
- Publication Type:Original Article
- Keywords:
Locally advanced breast cancer;
Neoadjuvant chemotherapy;
Radiation therapy
- MeSH:
Breast;
Breast Neoplasms;
Disease-Free Survival;
Follow-Up Studies;
Humans;
Lymph Nodes;
Multivariate Analysis;
Neoplasm Metastasis;
Retrospective Studies;
Survival Rate
- From:The Journal of the Korean Society for Therapeutic Radiology and Oncology
2010;28(2):71-78
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the result of neoadjuvant chemotherapy, surgery, and radiation therapy in locally advanced breast cancer as well as analyze the prognostic factors affecting survival. MATERIALS AND METHODS: One hundred fifty-nine patients with breast cancer were treated by neoadjuvant chemotherapy between April 1995 and November 2006 at the Samsung Medical Center. Among these patients, we retrospectively reviewed 105 patients treated with neoadjuvant chemotherapy followed by surgery and radiation therapy for a cure with an initial tumor size >5 cm or clinically positive lymph nodes. All patients received anthracycline based chemotherapy except for 2 patients. According to clinical tumor stage, 3 patients (3%) were cT1, 26 (25%) were cT2, 39 (37%) were T3 and 37 (35%) were T4. Initially, 98 patients (93%) showed axillary lymph node metastasis. The follow-up periods ranged from 7~142 months (median, 41 months) after the beginning of neoadjuvant chemotherapy. RESULTS: Locoregional failure free survival rate and distant metastasis free survival rate at 5 years were 82.1% and 69.9%, respectively. Disease free survival rate and overall survival rate at 5 years were 66.1% and 77.1%, respectively. The results of a univariate analysis indicate that clinical tumor stage, pathologic tumor stage, pathologic nodal stage and pathologic TNM stage were statistically significant factors for disease free survival rate and overall survival rate. Whereas, a multivariate analysis indicated that only hormone therapy was a statistically significant factor for survival. CONCLUSION: The current study results were comparable to other published studies for neoadjuvant chemotherapy for breast cancer. Hormone therapy was a statistically significant prognostic factor. The patients with early clinical or pathologic stage had a tendency to improve their survival rate.
